Table 2 Characteristics of the studies included in the meta-analysis
From: Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis
Study | Cohort characteristics | Country | Total numbers | Gender, (men%) | Age (mean ± SD) | Study design | Genotyping | Allele | HWE | Risk factors | Matching variables | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TA | T | |||||||||||
Stickel [11] | HCC | Swiss, German, Austrian, Italian, British | 1031 | 91.0 | 62 ± 10 | Case control study | TaqMan | 365 | 1697 | YES | Alcohol consumption | Age, gender, BMI, PNPLA3 (rs738409) |
ALD | 1653 | 84.0 | 48 ± 10 | 728 | 2578 | |||||||
Yang [12] | HCC | France | 178 | 83.0 | 64 | Case control study | TaqMan | 86 | 270 | YES | Alcohol consumption | Age, gender, PNPLA3 (rs738409) |
Viral hepatitis | 459 | 68.0 | 55 | 316 | 602 | |||||||
Fazio [13] | HCC | Italy | 123 | – | – | Case control study | TaqMan | 52 | 194 | – | NO | PNPLA3 (rs738409) |
NAFLD | 241 | – | 98 | 384 | ||||||||
Abul-Husn [14] | HCC | USA | 44 | 42.0 | 63 | Case control study | TaqMan | 12 | 76 | YES | Alcohol consumption | Age, gender, BMI |
NAFLD | 435 | 106 | 764 | |||||||||
Scheiner [15] | HCC | Vienna | 23 | – | – | Case control study | TaqMan | 10 | 40 | NO | Alcohol consumption | Age, gender, MELD, HVPG |
Viral hepatitis and NAFLD | 464 | 74.0 | – | 204 | 720 | |||||||
Abul-Husn [14] | HCC | USA | 44 | 42.0 | 63 | Case control study | TaqMan | 12 | 76 | YES | Alcohol consumption | Age, gender, BMI |
Healthy controls | 4279 | 1172 | 7386 | |||||||||
Yang [12] | HCC | France | 1018 | 83.0 | – | case control study | TaqMan | 692 | 1344 | YES | alcohol consumption | Age, gender, PNPLA3 (rs738409) |
Healthy controls | 503 | – | – | 402 | 604 | |||||||
Fazio [13] | HCC | Italy | 123 | – | – | Case control study | TaqMan | 52 | 194 | – | NO | PNPLA3 (rs738409) |
Healthy controls | 90 | – | 50 | 130 | ||||||||
Ting [16] | NAFLD | Malaya, China, India | 223 | 52.5 | 55.65 ± 12.5 | Case control study | TaqMan | 107 | 339 | – | NO | Age, gender, BMI, Blood pressure, |
Viral hepatitis | 205 | 42.4 | 51.0 ± 12.5 | 139 | 271 | |||||||
Di Sessa [17] | NAFLD | Italy | 318 | 53.3 | 10.7 ± 2.9 | Case control study | TaqMan | 200 | 436 | YES | NO | Age, gender, BMI, |
Healthy controls | 366 | 50.5 | 10.3 ± 2.3 | 334 | 398 | |||||||
Fazio [13] | NAFLD | Italy | 151 | – | – | Case control study | TaqMan | 48 | 254 | - | NO | PNPLA3 (rs738409) |
Healthy controls | 90 | – | 50 | 130 | ||||||||
Abul-Husn [14] | NAFLD | USA | 210 | 42.0 | 63 | Case control study | TaqMan | 46 | 374 | YES | alcohol consumption | Age, gender, BMI |
Healthy controls | 4279 | 1172 | 7386 | |||||||||
Scheiner [15] | NAFLD | Vienna | 202 | 76.0 | 59 ± 10 | Case control study | TaqMan | 89 | 315 | NO | NO | Age, gender, MELD, HVPG |
Viral hepatitis | 285 | 74.0 | 52 ± 9 | 125 | 445 | |||||||